![]() Detectnet has a longer half-life than Netspot which allows for more flexibility in ordering doses and scheduling patients. “Further discussion with the manufacturers is necessary,” the authors added. Previously, Netspot (Ga68) was the only approved PET tracer for evaluation of NETs. In addition, using a wider variety of generators to produce NETSPOT or using cyclotron-produced gallium chloride are two other methods that could improve production in a relatively short amount of time. For instance, “a temporary exemption to the 400-elution limit would have a major impact on NETSPOT capacity for patients,” according to the letter. SNMMI notes some possible remedies for this shortage. This has led to shortages throughout the United States. And those generators are only approved for either 400 uses or one year, whichever comes first. NETSPOT, however, is only approved using specific generators. Netspot (gallium Ga 68 dotatate) is a radioactive diagnostic agent indicated for use. Treatment for: Diagnosis and Investigation. Company: Advanced Accelerator Applications USA, Inc. ![]() Assay the dose in a suitable dose calibrator. FDA Approved: Yes (First approved June 1, 2016) Brand name: Netspot. Using aseptic technique and radiation shielding, withdraw the appropriate dose immediately prior to administration. ![]() The letter explains that Ga-68 is currently used to produce NETSPOT from Advanced Accelerator Applications, which was approved in June 2016 to help treat neuroendocrine tumors (NETs) in adult and pediatric patients using PET. Storage: After addition of gallium Ga 68 chloride to the reaction vial, use Ga 68 dotatate injection within 4 hours. Cutler, PhD, chair of the SNMMI Committee on Radiopharmaceuticals, and SNMMI President Satoshi Minoshima, MD, PhD. The letter-available here-is signed by Cathy S. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has written a letter to the FDA about ongoing shortages of generators that produce gallium-68 (Ga-68), a radioisotope used regularly in medical imaging. Another exciting step forward for the NET community Advanced Accelerator Applications announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOT® Transitional Pass-Through Status under an A-code (A9587) for drug reimbursement, effective January 1, 2017. ![]()
0 Comments
Leave a Reply. |